Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot studyGilles Freyer, Philippe Hennebert, Ahmad Awada, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumoursPatrick Schöffski, Ahmad Awada, Herlinde Dumez, et al.
Molecular and Clinical Oncology|September 3, 2016
Testicular germ cell tumor: Short and long-term side effects of treatment among survivorsThierry Gil, Spyridon Sideris, Fouad Aoun, et al.
Cancer Chemotherapy and Pharmacology|May 1, 2008
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyAhmad Awada, Martine J Piccart, Suzanne F Jones, et al.
Frontiers in Neuroscience|September 13, 2021
Digital Implementation of Oscillatory Neural Network for Image Recognition ApplicationsMadeleine Abernot, Thierry Gil, Manuel Jiménez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
<sup>68</sup>Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based ChemotherapyQaid Ahmed Shagera, Carlos Artigas, Ioannis Karfis, et al.
Clinical Nuclear Medicine|June 29, 2023
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With CabazitaxelQaid Ahmed Shagera, Ioannis Karfis, Spyridon Sideris, et al.
Cancers|October 13, 2021
Oligometastatic Disease Detection with <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical ImpactCarlos Artigas, Romain Diamand, Qaid Ahmed Shagera, et al.
European Urology|June 25, 2013
A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapyManfred Wirth, Axel Heidenreich, Jürgen E Gschwend, et al.
Annals of Nuclear Medicine|October 5, 2024
Evaluating response to radium-223 using <sup>68</sup>Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancerQaid Ahmed Shagera, Thierry Gil, Elisa Barraco, et al.
Pageof 5